Article
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
Zeitschrift fur Gastroenterologie - 1 Sept 2020
Vermehren Johannes, Serfert Yvonne, Cornberg Markus, Stoehr Albrecht, Klinker Hartwig, Simon Karl-Georg, Teuber Gerlinde, Deterding Katja, Schulze Zur Wiesch Julian, Jung Maria-Christina, Manns Michael P, Zeuzem Stefan, Wedemeyer Heiner, Sarrazin Christoph
Abstract excerpt
Despite the high effectiveness of direct-acting antivirals for the treatment of hepatitis C, a small proportion of patients do not respond to approved regimens. The combination regimen of SOF/VEL/VOX was recently approved for patients with failure to prior NS5A-based treatment. In this German real-world cohort including patients with cirrhosis (27.3 %) and previous decompensation events, 12 weeks of SOF/VEL/VOX...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.